Moore et al. further exacerbated this effect by using the nicotinamide phosphoribosyl transferase (NAMPT) inhibitor FK866, which contributed to an even stronger depletion of NAD+ pools as a strategy to target NQO1+ cancer types [65]. The gene discussed is NQO1; the disease is cancer.